Work

Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.7_suppl.548

Authors: Rana R. McKay, Bradley Alexander McGregor, Kathryn Gray, John A. Steinharter, Meghara K. Walsh, David A. Braun, Abdallah Flaifel, Eliezer VanAllen, Xiao X. Wei, Sabina Signoretti, Lauren Christine Harshman, Ulka N. Vaishampayan, Toni K. Choueiri

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Stanford Medicine, Stanford University, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921784259

Cites:

Cited by: 25

Related to: 10